27.05.2008 13:00:00

Cegedim and Skila Form Alliance to Co-Market Solutions to Life Science Industry

Cegedim and Skila have formed a global alliance to co-market their products and services to medical and marketing teams in the life sciences industry. The co-marketing alliance between Cegedim, a world leader in pharmaceutical CRM and strategic healthcare industry data, and Skila, a leader in integrated Marketing and Medical solutions, creates the industry’s most complete suite of knowledge and effectiveness solutions for global Medical and Marketing teams. The global alliance addresses the growing need for pharmaceutical companies to better understand their clients; streamline their global teams and business processes; ensure corporate transparency and internal medical and regulatory compliance; and get the most out of their key initiatives. "There is significant customer value in the partnership between Cegedim and Skila, particularly in the areas of medical and marketing effectiveness,” says Laurent Schockmel, CFO of Cegedim Americas. "Our customers are always looking for innovative end-to-end solutions in these areas, and this alliance will allow us to provide that.” The collaboration between Cegedim and Skila will focus on delivering extensive customer value by helping new and existing customers address the challenges and opportunities of launching new products and managing all aspects of thought leader relationships. "By working together, we offer our clients the industry’s most unique, robust and sustainable solutions for identifying and building lasting relationships with thought leaders, as well as maximizing the effectiveness of global product launches and the teams responsible for their success” follows Moish Tov, CEO of Skila. The Skila solutions that will be co-marketed are: iAdvocate: Unique technology and continuous services for building and managing lasting relationships with thought leaders based on the exchange of actionable knowledge, need and collaboration. Featuring real-time, dynamic 360-degree key opinion leader profiles; planning , targeting, and segmentation tools; meeting preparation and relationship management tools and services; and medical science liaison support and effectiveness tracking for each of these relationships. iLaunch: Unique technology and continuous services that enables global launch teams to maximize the effectiveness of their global team by centralizing knowledge and working as one team. iPerformance: Unique technology and continuous services that enable executives to achieve alignment and transparency in managing business performance across global and local brands and brand portfolios. The Cegedim solutions that will be co-marketed are: IcoMed: Measures physicians' preferential attachment to products that they prescribe while evaluating the size and profile of their clientele. This personal prescribing data allows pharmaceutical companies to define physician profiles and adapt their information strategies; measure the effectiveness of their information; and perform general interest studies on the markets in which they are present or that they wish to develop; OneKey: A comprehensive international healthcare professional database; and Physician Connect. Offers an advanced solution for identifying prescribers who influence peers' prescription writing behaviors. Physician Connect evaluates the existing ties among key opinion leaders and prescribers, and makes it possible to identify local networks of influence among physicians treating a specific pathology at the local, regional or national level, for therapeutic management and continuing education purposes. About Cegedim: Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, pharmaceutical companies, healthcare professionals and insurance companies. The world leader in pharmaceutical CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs more than 8,000 people in 80 countries and generated revenue of €753 million in 2007. To learn more, please visit our website: www.cegedim.com Listed on NYSE Euronext Paris, compartment B – ISIN FR0000053506 – Reuters CGDM.PA – Bloomberg CGM About Skila Skila is a global technology and services company specializing in knowledge and effectiveness solutions for the healthcare industry. Skila’s solutions address the broad needs of global marketing, medical, executive and alliance management teams. These solutions include a unique methodology, robust technology and key continuous services for effectively managing global product launches, key opinion leader relationships, business performance, competitive intelligence, and key partnerships and alliances. Having developed strong relationships with a broad number of global Pharmaceutical companies, Skila’s solutions have been deployed in 56 countries, supporting numerous global brands and over 10 million user interactions. Skila’s long-standing commitment and understanding of customers’ needs has resulted in the long-term growth and adoption of our methodology, technology and continuous services as the business platform of choice for many of our clients. To learn more about Skila visit our website at www.skila.com.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Nachrichten zu Cegedim S.A.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Cegedim S.A.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Cegedim S.A. 10,75 1,42% Cegedim S.A.

Indizes in diesem Artikel